Revive Therapeutics Ltd.
RVVTFOTCHealthcare● Active
$0.03
+$0.00(+17.69%)
Market Cap$11074888
P/E Ratio—
52W High$0.059
52W Low$0.006
Revive Therapeutics Ltd. (RVVTF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RVVTF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.02B | $0.01B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.01B |
| Total Operating Expenses | $0.00B | $0.00B | $0.01B | $0.02B | $0.02B |
| Operating Income | ($0.00B) | ($0.00B) | ($0.01B) | ($0.02B) | ($0.02B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.02B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) | ($0.02B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.03 | $-0.01 | $-0.02 | $-0.06 | $-0.08 |
| Wtd Avg Shares | 0.42B | 0.38B | 0.34B | 0.32B | 0.27B |
| EBITDA | ($0.01B) | ($0.00B) | ($0.01B) | ($0.02B) | ($0.02B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CAD · B
Explore more Revive Therapeutics Ltd. data
About Revive Therapeutics Ltd. (RVVTF) Income Statement
Revive Therapeutics Ltd. (RVVTF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RVVTF reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
RVVTF · 4 questionsRevive Therapeutics Ltd. (RVVTF) reported revenue of $0.00B for 2025, down —% year-over-year.
RVVTF revenueRVVTF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09